Objective: To observe the clinical spectrum, complications and pregnancy outcome in women with Hepatitis E.
Methods: The descriptive prospective study was conducted at the Liaquat University of Medical and Health Sciences, Jamshoro, Red Crescent General Hospital and Saint Elizabeth Hospital, Hyderabad, from January 1, 2011, to December 31, 2013. All pregnant women with Hepatitis E positive on virology screening were included. The subjects were enrolled from the out-patient department as well as from among those admitted in either Obstetrics or Medical wards. Data was obtained through a predesigned proforma, and analysed using SPSS 20.
Results: The overall mean age of the 45 women in the study was 27.78±6.742. There were 21(46.7%) women in 21-30 years age group, 22(48.9) were multiparous, 31(68.9%) were uneducated, and 29(64.4%) were from poor social class. Besides, late second trimester and third trimester of pregnancy was found in 27(60%), unstable condition 10(22.22%), disturbed liver function test 24(53.3%) and raised serum glutamic pyruvic transaminase level >101u/l 27(60%), deranged coagulation profile such as raised prothrombin time 25(55.5%), and activated partial thromboplastin time 18(40%)cases. Overall 36(80%) women were discharged, while 9 (20%) died. Besides, 10(24.4%) babies needed intensive care, 13(42.2%) foetuses died during intrauterine life, 5(11%) were stillborn, while 17(37.8%) were alive and were discharged home.
Conclusions: Pregnant women with Hepatitis E were more vulnerable as their life, health and foetal outcome suffered a lot.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Hainan Women and Children's Medical Center, Haikou, 571199, Hainan, China.
This observational investigation aimed to explore potential risk factors for anemia in pregnancy. Firstly, a cross-sectional study was conducted, encompassing a review of clinical data of 43,201 pregnant women admitted to the Hainan Women and Children's Medical Center between January 2017 and December 2020. Comparison between women with and without anemia in pregnancy revealed significant differences between the two groups concerning age, gestational diabetes, hypothyroidism, hyperthyroidism, chronic hepatitis B virus infection, syphilis infection, and human immunodeficiency virus infection.
View Article and Find Full Text PDFClin Rheumatol
January 2025
Department of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
Introduction/objectives: The study aimed to determine whether in children with newly diagnosed juvenile idiopathic arthritis (JIA) hepatitis B surface antibody (anti-HBs) differs from healthy children and to see whether the revaccination is safe and effective under JIA treatment.
Methods: Patients who were followed up with a diagnosis of JIA between January 2020 and February 2024 were included. The control group consisted of healthy children matched for age and gender.
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan.
Background: Plasma AST and ALT may reflect the nonalcoholic fatty liver disease (NAFLD) severity and have been associated with the risk of MetS in middle- or old-aged individuals.
Aims: This study aimed to examine the associations of plasma hepatic aspartate and alanine transaminases (AST and ALT) levels with incident metabolic syndrome (MetS) in young adults, which have not been verified before.
Objective: The goal of this study was to identify the association between plasma hepatic transaminases and the incidence of new-onset MetS among young adults.
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan.
Background: Hepatic inflammation, e.g., Nonalcoholic Fatty Liver Diseases (NAFLD) and the severe form of steatohepatitis (NASH), has been associated with a higher risk of MetS in the general population.
View Article and Find Full Text PDFLancet Microbe
January 2025
Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Background: R21 is a novel malaria vaccine, composed of a fusion protein of the malaria circumsporozoite protein and hepatitis B surface antigen. Following favourable safety and immunogenicity in a phase 1 study, we aimed to assess the efficacy of R21 administered with Matrix-M (R21/MM) against clinical malaria in adults from the UK who were malaria naive in a controlled human malaria infection study.
Methods: In this open-label, partially blinded, phase 1-2A controlled human malaria infection study undertaken in Oxford, Southampton, and London, UK, we tested five novel vaccination regimens of R21/MM.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!